Amgen Inc. vs Geron Corporation: Strategic Focus on R&D Spending

Strategic Focus on R&D: Amgen Inc. vs Geron Corporation

In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Amgen Inc. and Geron Corporation have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Amgen consistently allocated substantial resources to R&D, with expenditures peaking at approximately $4.8 billion in 2021, reflecting a 35% increase from 2017. This robust investment underscores Amgen's strategic focus on maintaining its leadership in the biotech sector.

Conversely, Geron Corporation, a smaller player, has shown a more modest yet significant increase in R&D spending. Starting at around $11 million in 2017, Geron's R&D expenses surged by over 1000% to reach approximately $125 million in 2023. This dramatic rise highlights Geron's aggressive push towards innovation, potentially positioning it as a formidable contender in the industry.